Novel non-operative treatment and treatment strategies in pancreatic cancer

Bibliography

• OPCS: Mortality statistics - cause. HMSO, London, UK (1992). Report No.: DH2 no.19.
   Google Scholar
• BORING CC, SQUIRES TS, TONG T: Cancer statistics, 1993. Cancer J. Clin. (1993) 43(1):7–26.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, ALLUM WH, JONES AG et al.: Incidence, treatment and survival in 13,560 patients with pancre-atic cancer: An epidemiological study in the West Midlands. Br. J. Surg. (1995) 82(1):111–115.
   PubMed Web of Science ®Google Scholar
• ••A very large epidemiological study.
   Google Scholar
• TREDE M, SCHWALL G, SAEGER HD: Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann. Surg. (1990) 211(4):447–458.
   Google Scholar
• ••Pivotal paper on surgical resection in pancreatic cancer.
   Google Scholar
• GALL FP, KESSLER H, HERMANEK P: Surgical treatment of ductal pancreatic carcinoma. Eur. J. Surg. Oncol. (1991) 17(2):173–181.
   PubMedGoogle Scholar
• CAMERON JL, PITT HA, YEO CJ et al.: One hundred and forty-five consecutive pancreatoduodenectomies without mortality. Ann. Surg. (1993) 217(5):430–438.
   PubMed Web of Science ®Google Scholar
• GUDJONSSON B: Cancer of the pancreas 50 years of surgery. Cancer (1987) 60(9):2284–2303.
   PubMed Web of Science ®Google Scholar
• •Epidemiological review of pancreatic cancer.
   Google Scholar
• ARBUCK SG: Chemotherapy for pancreatic cancer. Baillieres Clin. Gastroenterol. (1990) 4(4):953–968.
   PubMedGoogle Scholar
• MOERTEL CG, RUBIN J, O'CONNELL MJ: A Phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of upper gastrointestinal adenocarci-nomas. J. Clin. Oncol. (1986) 4:1053–1057.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY JB, KELSEN D, KEMENY N et al.: Advanced pancreatic cancer: a Phase I-II trial of cisplatin, high-dose cytarabine and caffeine. J. Natl. Cancer Inst. (1989) 81 (22): 1735–1738 .
   PubMed Web of Science ®Google Scholar
• LINK KH, GANSAUGE F, GORICH J et al.: Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur. J. Surg. Oncol. (1997) 23:409–414.
   PubMed Web of Science ®Google Scholar
• CULLINAN S, MOERTEL CG, WIEAND HS et al.: A Phase DI trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer (1990) 65(10):2207–2212.
   Google Scholar
• KELSEN D, HUDIS C, NIEDZWIECKI D et al A Phase DI comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma. Cancer (1991) 68(5):965–969.
   PubMed Web of Science ®Google Scholar
• OKUSAKA T, OKADA S, ISHII H et al.: Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J. Clin. Oncol. (1996) 26(4):215–220.
   PubMed Web of Science ®Google Scholar
• WILS JA, KOK T, WAGENER DJT, SELLESLAGS J, DUEZ N: Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer (1993) 29A(2):203–204.
   PubMed Web of Science ®Google Scholar
• MALLINSON CN, RAKE MD, COCKING JB et al.: Chemotherapy in pancreatic cancer: results of a controlled prospective randomised, muhicentre trial. Br. Med. J. (1980) 281:1589–1591.
   PubMed Web of Science ®Google Scholar
• PALMER KR, KERR M, KNOWLES G et al.: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br. J. Surg. (1994) 81(6):882–885.
   PubMed Web of Science ®Google Scholar
• EVANS DB, ABBRUZZESE JL, RICH TA: Cancer of the Pancreas. In: Principles &Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA, (Eds.) Lippincott-Raven, Philadel-phia, US (1997):1054–1087.
   Google Scholar
• GASTROINTESTINAL TUMOUR STUDY GROUP: Therapy of locally unresecTable pancreatic carcinoma: A randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. Cancer (1981) 48(8):1705–1710.
   PubMed Web of Science ®Google Scholar
• BAUMEL H, HUGUIER M, MANDERSCHEID JC et al.: Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br. J. Surg. (1994) 81(1):102–107.
   PubMed Web of Science ®Google Scholar
• ••Large review of the French surgical experience with pancre-atic cancer.
   Google Scholar
• WILLETT CG, LEWANDROWSKI K, WARSHAW AL, EFIRD J, COMPTON CC: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg. (1993) 217(2):144–148.
   Web of Science ®Google Scholar
• SPLINTER TA, OBERTOP H, KOK TC, JEEKEL J: Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study. J. Cancer Res. Clin. Oncol. (1989) 115(2):200–202.
   PubMed Web of Science ®Google Scholar
• BAKKEVOLD KE, ARNESJO B, DAHL O, KAMBESTAD B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised muhicentre study. Eur. J. Cancer (1993) 5:698–703.
   Google Scholar
• KALSER MH, ELLENBERG SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. (1985) 120:899–903.
   PubMed Web of Science ®Google Scholar
• ••The basis for most adjuvant therapy in pancreatic cancer.
   Google Scholar
• GASTROINTESTINAL TUMOUR STUDY GROUP: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancre-atic cancer. Cancer (1987) 59(12):2006–2010.
   PubMed Web of Science ®Google Scholar
• NEOPTOLEMOS JP, MEMBERS OF THE UK PANCREATIC CANCER GROUP: Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic Cancer Results of the UK Pancreatic Cancer Group study (UKPACA-1). GI Cancer (1998) 2(3):235–245.
   Web of Science ®Google Scholar
• CASPER ES, GREEN MR, KELSEN DP et al.: Phase II trial of gemcitabine in patients with adenocarcinoma of the pancreas. Invest. New Drugs (1994) 12:29–34.
   PubMed Web of Science ®Google Scholar
• CARMICHAEL J, FINK U, RUSSELL RCG et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer (1995) 73:101–105.
   Web of Science ®Google Scholar
• ROTHENBERG ML, ABBRUZZESE JL, MOORE M et al.: A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer (1996) 78(3):627–632.
   PubMed Web of Science ®Google Scholar
• •The basis for incorporation of quality of life end points in clinical trials in pancreatic cancer.
   Google Scholar
• BURRIS H, STORNILOL AM: Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared with 5-fluorouracil. Eur. J. Cancer (1997) 33\(Suppl. 1):518–522.
   Google Scholar
• BURRIS HA, MOORE MJ, ANDERSEN J et al.: Improve-ments in survival and clinical benefit with gemcita-bine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. (1997) 15(6):2403–2413.
   PubMed Web of Science ®Google Scholar
• •The first randomised evidence in support of chemotherapy for advanced pancreatic cancer.
   Google Scholar
• ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. (1996) 7(4):347–353.
   PubMed Web of Science ®Google Scholar
• STORNIOLO AM, ENAS NH, BROWN CA et al.: An investi-gational new drug treatment program for patients with gemcitabine. Cancer (1999) 85(6):1261–1268.
   PubMed Web of Science ®Google Scholar
• CRINO L, MOSCONI AM, CALANDRI C et al.: Gemcitabine in advanced pancreatic cancer: a Phase II trial. Eur. J. Cancer (1997) 33:A1266.
   Web of Science ®Google Scholar
• MANZANO H, ESQUERDO G, RIFA J etai.: Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC). Ann. Oncol. (1998) 9\(Suppl. 4):A256.
   Google Scholar
• PETROVIC Z, JOVIC J, PERISIC N, BROCICPECELJ T, LUKACEVIC S: Monotherapy with gemcitabine in patients with advanced pancreatic carcinoma. Ann. Oncol. (1998) 9\(Suppl. 2):167.
   Google Scholar
• SPITZ FR, ABBRUZZESE JL, LEE JE et al.: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocar-cinoma of the pancreas. J. Clin. Oncol. (1997) 15(3):928–937.
   PubMed Web of Science ®Google Scholar
• YEO CJ, ABRAMS RA, GROCHOW LB et al.: Pancreatico-duodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann. Surg. (1997) 225(5):621–633.
   Google Scholar
• PETERS GJ, BERGMAN AM, RUIZ VAN HAPEREN VW et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. (1995) 22(4 Suppl. 11):72–79.
   Google Scholar
• PETERS GJ, RUIZ VAN HAPEREN VW, BERGMAN AM et al.: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. (1996) 23(5 Suppl. 10):16–24.
   Google Scholar
• SANDLER AB, NEMUNAITIS J, DENHAM C et al.: Phase HI trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2000) 18(1):122–130.
   PubMed Web of Science ®Google Scholar
• CARDENAL F, LOPEZ-CABRERIZO MP, ANTON A et al.:Randomized Phase BI study of gemcitabine-cisplatin versus etoposide- cisplatin in the treatment of locally advanced or metastatic non-small- cell lung cancer. J. Clin. Oncol. (1999) 17(1):12–18.
   PubMed Web of Science ®Google Scholar
• LIPPE P, TUMMARELLO D, MONTERUBBIANESI MC et al.:Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase II study. Ann. Oncol. (1999) 10(2):217–221.
   PubMed Web of Science ®Google Scholar
• COLUCCI G, GIULIANI F, RICCARDI F et al.: Gemcitabinealone or with cisplatin in advanced pancreatic cancer: Preliminary results of a randomized study of the Southern Italy Oncology Group. Pro. ASCO (1998) 17:289A.
   Google Scholar
• PILEPICH MV, MILLER HH: Preoperative irradiation in carcinoma of the pancreas. Cancer (1980) 46(9)1945–1949.
   Google Scholar
• KOPELSON G: Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: The role of adjuvant pre or postoperative radiation therapy. Intl. Radiation Oncol. Biol. Phys. (1983) 9:911–915.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA O, OHHIGASHI H, TESHIMA T et al.: Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduo-denal region. J. Surg. Oncol. (1989) 40(3):143–151.
   PubMed Web of Science ®Google Scholar
• WEESE JL, NUSSBAUM ML, PAUL AR et al.: Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemora-diotherapy. Int. J. Pancreatol. (1990) 7(1-3):177–185.
   PubMedGoogle Scholar
• EVANS DB, RICH TA, BYRD DR et al.: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg. (1992) 127(11):1335–1339.
   PubMed Web of Science ®Google Scholar
• PISTERS PW, HUDEC WA, LEE JE et al.: Preoperativechemoradiation for patients with pancreatic cancer: Toxicity of endobiliary stents. J. Chn. Oncol. (2000) 18(4):860.
   PubMed Web of Science ®Google Scholar
• STALEY CA, LEE JE, CLEARY KR et al.: Preoperativechemoradiation, pancreaticoduodenectomy and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am. J. Surg. (1996) 171(1):118–124.
   PubMed Web of Science ®Google Scholar
• BRESLIN TM, JANJAN NA, LEE JE et al.: Neoadjuvantchemoradiation for adenocarcinoma of the pancreas. Front Biosci. (1998) 3:E193–E203.
   PubMedGoogle Scholar
• HOFFMAN JP, WEESE JL, LIPSITZ S et al.: Preoperativechemoradiation for patients with resectable pancre-atic adenocarcinoma: an Eastern Cooperative Oncology Group (ECOG) Phase II study. Proc. ASCO. (1995)14:214.
   Google Scholar
• RICH TA, JANJAN NA, ABBRUZZESE JL, EVANS DB: (Response) Preoperative and postoperative chemora-diation strategies in patients treated with pancreatico-duodenectomy for adenocarcinoma of the pancreas./ Clin. Oncol. (1997) 15:3292–3293.
   Google Scholar
• LAWRENCE TS, CHANG EY, HERTEL L, SCHEWACH B: Gemcitabine radiosensitises human pancreas cancer cells. Proc. AACR. (1994) A3855.
   Google Scholar
• COTTAM. DW, REES RC: Regulation of matrix metallo-proteinases: their role in tumor invasion and metastasis (review). Int. J. Oncol. (1993) 2:861–872.
   PubMed Web of Science ®Google Scholar
• •Useful early review of MMPs in cancer.
   Google Scholar
• STETLER-STEVENSON WG, KRUTZSCH HC, LIOTTA LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. (1989) 264(29):1737447378.
   Google Scholar
• URIA JA, FERRANDO AA, VELASCO G, FREIJE JMP, LOPEZ-OTIN C: Structure and expression in breast tumours of human TIMP-3, a new member of the metalloprote-inase inhibitor family. CancerRes. (1994) 54:2091–2094.
   Web of Science ®Google Scholar
• KHOKHA R, WATERHOUSE P, YAGEL S et al.: AntisenseRNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science (1989) 243:947–950.
   PubMed Web of Science ®Google Scholar
• ALVAREZ OA, CARMICHAEL DF, DECLERCK YA: Inhibi-tion of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst. (1990) 82(7):589–595.
   PubMed Web of Science ®Google Scholar
• SCHULTZ RM, SILBERMAN S, PERSKY B, BAJKOWSKI AS,CARMICHAEL DF: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonisation by murine B1 6-F1 0 melanoma cells. Cancer Res. (1 9 8 8) 48:5539-5545.
   Google Scholar
• DECLERCK YA, YEAN T-D, LU HS, TING J, LANGLEY KE:Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J. Biol. Chem. (1 9 9 1) 266(6):3893–3899.
   Google Scholar
• ALBINI A, MELCHIORI A, SANTI L et al.: Tumor cellinvasion inhibited by TIMP-2. J. Natl. Cancer Inst. (1991) 83a0:775–779.
   Google Scholar
• DECLERCK YA, HAMMANI K, KOHN D, IMREN S: Tissue inhibitors of matrix metalloproteinases in tumor growth. In: Proteases and Protease Inhibitors: AACR Special Conference. Matrisian LM, Sloane BF (Eds.), Marriott's Bay Point Resort, Panama City Beach, Florida, US (1996).
   Google Scholar
• KAWAMATA H, KAWAI K, KAMEYAMA S et al.: Over-expression of tissue inhibitor of matrix metallo-proteinases (TIMP1 and TIMP2) suppresses extravasa-tion of pulmonary metastasis of a rat bladder carcinoma. Int. J. Cancer (1995) 63:680–687.
   PubMed Web of Science ®Google Scholar
• KHOKHA R: Tumor development in TIMP-1 transgenic mice. In: Proteases and Protease Inhibitors: AACR Special Conference. Matrisian LM, Sloane BF (Ed..) Marriott's Bay Point. Resort, Panama City Beach, Florida, USA (1996).
   Google Scholar
• CAMPO E, MERINO MJ, TAVASSOLI FA eta/.: Evaluation of basement membrane components and the 72 ItDa Type IV collagenase in serous tumors of the ovary. Am. J. Surg. Pathol. (1992) 16(5):500–507.
   Google Scholar
• POLETTE M, CLAVEL C, BIREMBAUT P, DE-CLERCK YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol. Res. Pract. (1993) 189(9):1052–1057.
   PubMed Web of Science ®Google Scholar
• MULLER D, WOLF C, ABECASSIS J et al Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res (1993) 53(1):165–169.
   PubMed Web of Science ®Google Scholar
• URBANSKI SJ, EDWARDS DR, MAITLAND A et al.: Expres-sion of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br. J. Cancer (1992) 66(6)1188–1194.
   Google Scholar
• BRAMHALL SR, NEOPTOLEMOS JP, STAMP GWH, LEMOINE NR: Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J. Pathol. (1997) 182:347–355.
   PubMed Web of Science ®Google Scholar
• TAKINO T, SATO H, SHINAGAWA A, SEIKI M: Identifica-tion of the second membrane-type matrix metallopro-teinase (MT-MMP-2) gene from a human placenta cDNA library. J. Biol. Chem. (1995) 270(39):23013–23020.
   PubMed Web of Science ®Google Scholar
• SATO H, TAKINO T, KINOSHITA T, SEIKI M: Membrane-type matrix metalloproteinase (MT-MMP) -1, -2, -3 are activator of gelatinase A/72 kDa-type IV collagenase. In: Proteases and protease inhibitors: AACR Special Confer-ence. Matrisian LM, Sloane BF (Eds.) Marriott's Bay Point. Resort, Panama City Beach, Florida, USA (1996).
   Google Scholar
• SLEDGE GW, JR., QULALI M, GOULET R, BONE EA, FIFE R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. (1995) 87(20):1546–1550.
   PubMed Web of Science ®Google Scholar
• DAVIES B, BROWN PD, EAST N, CRIMMIN MJ, BALKWILL FR A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res (1993) 53(9):2087–2091.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MORRIS TM, ROBINSON G et al.: Inhibitionof organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. (1995) 55:3629–3633.
   PubMed Web of Science ®Google Scholar
• ECCLES SA, BOX GM, COURT WJ et al.: Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB94). Cancer Res. (1996) 56:2815–2822.
   PubMed Web of Science ®Google Scholar
• DOCHERTY AJP, BIRCH ML, CHANDER S et al.: Metallo-proteinase inhibitors in the treatment of cancer. In: Pmteases and Protease Inhibitors: AACR Special Conference. Matrisian LM, Sloane BF (Eds.) Marriott's Bay Point. Resort, Panama City Beach, Florida, USA (1996).
   Google Scholar
• TARABOLETTI G, GAROFALO A, BELOTTI D et al Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metallo-proteinases. J. Natl. Cancer Inst. (1995) 87(4):293–298.
   PubMed Web of Science ®Google Scholar
• MACAULAY VM, O'BYRNE KJ, SAUNDERS MP et al : PhaseI study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. (1999) 5(3):513–520.
   PubMed Web of Science ®Google Scholar
• BROWN PD: Clinical studies with matrix metalloprote-inase inhibitors. Apmis (1999) 107(1):174–180.
   PubMed Web of Science ®Google Scholar
• JONES L, GHANEH P, HUMPHREYS M, NEOPTOLEMOS JP:The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. NY Acad. Sci. (1999) 880:288–307.
   PubMed Web of Science ®Google Scholar
• ROSEMURGY A, HARRIS J, LANGLEBEN A et al.: Marirnastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. (1999) 22(3):247–252.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, POOLE C, PRIMROSE J et al.: Combinedanalysis of studies of the effects of the matrix metallo-proteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4(5):1101–1109.
   PubMedGoogle Scholar
• •First evidence of a biological effect of MMP inhibition in patients.
   Google Scholar
• EVANS J, BRAMHALL S, CARMICHAEL J et al.: A Phase IIstudy of marirnastat in advanced pancreatic cancer (Abstract 239). Ann. Oncol. (1996) 7(5):47.
   Google Scholar
• MALTESE WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. EASES J. (1990) 4(15):3319–3328.
   Google Scholar
• MANNE V, ROBERTS D, TOBIN A et al.: Identification andpreliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. USA (1990) 87(19):7541–7545.
   PubMed Web of Science ®Google Scholar
• SCHABER MD, O'HARA MB, GARSKY VM et al.: Polyiso-prenylation of Ras in vitro by a farnesyl-protein transferase. J. Biol. Chem. (1990) 265(25):14701–14704.
   Google Scholar
• REISS Y, GOLDSTEIN JL, SEABRA MC, CASEY PJ, BROWNMS: Inhibition of purified p2lras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell (1990) 62(1):81–88.
   PubMed Web of Science ®Google Scholar
• ITO T, KAWATA S, TAMURA S et al Suppression ofhuman pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn sf Cancer Res (1996) 87(2):113–116.
   PubMed Web of Science ®Google Scholar
• NAGASU T, YOSHIMATSU K, ROWELL C, LEWIS MD, GARCIA AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. (1995) 55(22):5310–5314.
   PubMed Web of Science ®Google Scholar
• KOHL NE, WILSON FR, MOSSER SD et al.: Proteinfarnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA (1994) 91(19):9141–9415.
   PubMed Web of Science ®Google Scholar
• KORC M: Role of growth factors in pancreatic cancer.Surg. Oncol. Clin. N. Am. (1998) 7(1):25–41.
   Google Scholar
• •Useful review of growth factor expression in pancreatic cancer.
   Google Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Coexpres-sion of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. AntiCancer Res (1993) 13(3):565–569.
   PubMed Web of Science ®Google Scholar
• WATSON S, DURRANT L, ELSTON P, MORRIS D: Inhibi-tory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumor cells. Cancer (1991) 68(6)1255–1260.
   Google Scholar
• ROBERTSON JF, WATSON SA, HARDCASTLE JD: Effect ofgastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int. J. Cancer (1995) 63(1)69–75.
   Google Scholar
• WATSON SA, CROSBEE DM, MORRIS DL et al.: Therapeutic effect of the gastrin receptor antagonist, CR2093 on gastrointestinal tumour cell growth. Br. J. Cancer (1992) 65(6):879–883.
   PubMed Web of Science ®Google Scholar
• IWASE K, EVERS BM, HELLMICH MR et al Regulation of growth of human gastric cancer by gastrin and glycine- extended progastrin. Gastroenterol (1997) 113(3):782–90.
   PubMed Web of Science ®Google Scholar
• DARRO F, CAMBY I, KRUCZYNSKI A et al Characterisation of the influence of anti-gastrin, anti-epidermal growth factor, anti-oestradiol and anti-luteinising hormone releasing hormone antibodies on the prolif-eration of 27 cell lines from the gastrointestinal tract. Gut (1995) 3 6(2) 220–230
   Google Scholar
• HOOSEIN NM, KIENER PA, CURRY RC et al Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res (1988) 48(24 Pt 1):7179–7183.
   Google Scholar
• WATSON SA, MICHAELI D, GRIMES S et al : Anti-gastrin antibodies raised by gastrirnmune inhibit growth of the human colorectal tumour AP5. Int. J. Cancer (1995) 61(2)233–240.
   Google Scholar
• WATSON SA, MICHAEL D, JUSTIN TA et al.: Pre-clinical evaluation of the Gastrimmune irnmunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Int. J. Cancer (1998) 75(6)873–877.
   Google Scholar
• WATSON SA, MICHAELI D, GRIMES S et al Gastrirnmune raises antibodies that neutralize arnidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res (1996) 56(4):880–885.
   PubMed Web of Science ®Google Scholar
• LIU TJ, ZHANG WW, TAYLOR DL et al : Growth suppres-sion of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombi-nant adenovirus. Cancer Res. (1994) 54:3662–3667.
   PubMed Web of Science ®Google Scholar
• EL-DEIRY WS, TOKINO T, VELCULESCU YE et al.: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75(4)817–825.
   Google Scholar
• CHEN PL, CHEN YM, BOOKSTEIN R, LEE WH: Genetic mechanisms of tumor suppression by the human p53 gene. Science (1990) 250(4987):1576–1580.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR: Molecular advances in pancreatic cancer. Digestion (1997) 58(6):550–556.
   PubMed Web of Science ®Google Scholar
• BARTON CM, STADDON SL, HUGHES CM et al.: Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer (1991) 64:1076–1082.
   PubMed Web of Science ®Google Scholar
• REDSTON MS, CALDAS C, SEYMOUR AB et al p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 54(11):3025–3033.
   PubMed Web of Science ®Google Scholar
• KALTHOFF H, SCHMIDT A, ROEDER C, SCHMEIGEL W: Alterations of p53 in benign lesions outnumber those in their malignant counterpart. Intl. Pancreatol. (1993) 14:92.
   Google Scholar
• KALTHOFF H, SCHMIEGEL W, ROEDER C: P53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene (1993) 8:289–293.
   PubMed Web of Science ®Google Scholar
• RUGGERI BA, HUANG L, BERGER D et al.: Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2 and p21/WAF-1 genes in sporadic and familial lesions. Cancer (1996) 79(4):700–716.
   Web of Science ®Google Scholar
• FREBOURG T, SADELAIN M, NG YS, KASSEL J, FRIEND SH: Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. (1994) 54(4):878–881.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, CAI DW, GEORGES RN et al.: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. (1994) 86(19):1458–1462.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, TRAPNELL BC, MITTEREDER N et al.: Transduction of normal and malignant oral epithe-lium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther. (1995) 2(2):105–111.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, EL-NAGGAR AK, ROTH JA et al.: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res (1995) 55(1):1–6.
   PubMed Web of Science ®Google Scholar
• CLAYMAN GL, LIU TJ, OVERHOLT SM et al.: Gene therapy for head and neck cancer comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Arch. Otolaryngol. Head Neck Surg. (1996) 122(5):489–493.
   PubMed Web of Science ®Google Scholar
• LIU TJ, EL-NAGGAR AK, MCDONNELL TJ et al Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res (1995) 55(14):3117–3122.
   PubMed Web of Science ®Google Scholar
• YANG C, CIRIELLI C, CAPOGROSSI MC, PASSANITI A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. (1 9 9 5) 55(19):4210–4213.
   Google Scholar
• FUJIWARA T, GRIMM EA, MUKHOPADHYAY T et al.: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. CancerRes.(1993) 53(18):4129–4133.
   Web of Science ®Google Scholar
• ASHTON WT, KARKAS JD, FIELD AK, TOLMAN RL: Activa-tion by thymidine kinase and potent antiherpetic activity of 2'- nor-2'-deoxyguanosine (2'NDG). Biochem. Biophys. Res. Commun. (1982) 108(4):1716–1721.
   PubMed Web of Science ®Google Scholar
• AOKI K, YOSHIDA T, MATSUMOTO N eta/.: Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum. Gene Ther. (1997) 8(9):1105–1113.
   Google Scholar
• YANG L, HWANG R, PANDIT L et al.: Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. (1996) 224(3):405–414.
   PubMed Web of Science ®Google Scholar
• HWANG HC, SMYTHE WR, ELSHAMI AA et al.: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. (1995) 13(1):7–16.
   PubMed Web of Science ®Google Scholar
• VILE RG, NELSON JA, CASTLEDEN S, CHONG H, HART IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. (1994) 54(23):6228–34.
   PubMed Web of Science ®Google Scholar
• GHOUMARI AM, RIXE O, YAROVOI SV et al.: Gene transfer in hepatocarcinoma canines: in vitro optimi-zation of a virus-free system. Gene Ther (1996) 3(6):483–490.
   PubMed Web of Science ®Google Scholar
• COBB LM, CONNORS TA, ELSON LA et al.: 2,4-dinitro-5-ethyleneirninobenzarnide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. (1969) 18(6):1519–1527.
   PubMed Web of Science ®Google Scholar
• FRIEDLOS F, COURTS, FORD M, DENNY WA, SPRINGER C: Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. (1998) 5(1):105–12.
   PubMed Web of Science ®Google Scholar
• ROBERTS JJ, FRIEDLOS F, KNOX RJ: CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. (1986) 140(3):1073–1078.
   PubMed Web of Science ®Google Scholar
• KNOX RJ, FRIEDLOS F, JARMAN M et al.: Virtual cofactors for an Escherichia coli nitroreductase enzyme: relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. (1995) 49(11):1641–1647.
   PubMed Web of Science ®Google Scholar
• AUSTIN EA, HUBER BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. (1993) 43(3):380–387.
   PubMed Web of Science ®Google Scholar
• MULLEN CA, KILSTRUP M, BLAESE RM: Transfer of the bacterial gene for cytosine deanninase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA (1992) 89(1):33–37.
   PubMed Web of Science ®Google Scholar
• HARRIS JD, GUTIERREZ AA, HURST HC, SIKORA K, LEMOINE NR: Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. (1994) 1(3):170–175.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, DRANOFF G, COHEN LK et al.: High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. (1993) 53\(Suppl. 10):2221–2226.
   Google Scholar
• DIMAIO JM, CLARY BM, VIA DF et al.: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery (1994) 116(2):205–213.
   PubMed Web of Science ®Google Scholar
• CLARY BM, LYERLY HK: Gene therapy and pancreatic cancer. Surg. Oncol. Clin. N. Am. (1998) 7(1):217–249.
   PubMedGoogle Scholar
• LEMOINE NR, HALL PA: Growth factors and oncogenes in pancreatic cancer. Clin. Gastroenterol. (1990) 4(4):815–832.
   Google Scholar
• BOS JL: Ras oncogenes in human cancer: a review. Cancer Res. (1989) 49(17):4682–4689.
   PubMed Web of Science ®Google Scholar
• •Useful early review of ras in human cancer.
   Google Scholar
• GRUNEWALD K, LYONS J, FROHLICH A et al.: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer (1989) 43(6):1037–1041.
   PubMed Web of Science ®Google Scholar
• TADA M, YOKOSUKA O, OMATA M, OHTO M, ISONO K: Analysis of ras gene mutations in biliary and pancre-atic tumors by polymerase chain reaction and direct sequencing. Cancer (1990) 66(5):930–935.
   PubMed Web of Science ®Google Scholar
• STORK P, LODA M, BOSARI S et al.: Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene (1991) 6:857–862.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, JAIN S, HUGHES CM eta/.: Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroen-terology (1992) 102:230–236.
   Google Scholar
• PELLEGATA NS, SESSA F, RENAULT B et al.: K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. (1994) 54(6):1556–1560.
   PubMed Web of Science ®Google Scholar
• FOSSUM B, GEDDE-DAHL T, BREIVIK J et al.: p21-ras-peptide-specific T-cell responses in a patient with colorectal Cancer CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-Asp). Int. J. Cancer (1994) 56(1):40–45.
   PubMed Web of Science ®Google Scholar
• GEDDE-DAHL TD, FOSSUM B, ERIKSEN JA, THORSBY E, GAUDERNACK G: T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and 111.4 restriction. Eur. J. Immunol (1993) 23(3):754–760.
   Google Scholar
• GEDDE-DAHL TD, SPURKLAND A, ERIKSEN JA, THORSBY E, GAUDERNACK G: Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-Leu61). Int. Immunol. (1992) 4(11):1331–1337.
   PubMed Web of Science ®Google Scholar
• FOSSUM B, OLSEN AC, THORSBY E, GAUDERNACK G: CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (G1y13—>Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunol. Immunother. (1995) 40(3):165–172.
   PubMed Web of Science ®Google Scholar
• GJERTSEN MK, BJORHEIM J, SAETERDAL I, MYKLEBUST J, GAUDERNACK G: Cytotoxic CD4+ and CD8+ T lympho-cytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer (1997) 72(5):784–790.
   PubMed Web of Science ®Google Scholar
• GEDDE-DAHL T, NILSEN E, THORSBY E, GAUDERNACK G: Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. Cancer Immunol. Immunother. (1994) 38(2):127–134.
   PubMed Web of Science ®Google Scholar
• DOUGLASS HO: Pancreatic cancer: Nihilism is obsolete! Pancreas (1987) 2(2):230–232.
   PubMed Web of Science ®Google Scholar
• NEOPTOLEMOS J, RUSSELL RCG, BRAMHALL SR, THEIS B, (UKPACA). FOR THE UK PANCREATIC CANCER GROUP: Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of pancreatic specialist units. Br. J. Surg. (1997) 84(10):1370–1376.
   Google Scholar
• •Important study relating surgical case load with operative mortality.
   Google Scholar
• KLINKENBIJL JH, JEEKEL J, SCHMITZ PI et al.: Carcinoma of the pancreas and periampullary region: palliation versus cure. Br. J. Surg. (1993) 80(12):1575–1578.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON EH, WELTON ML, REBER HA: Surgical treatment of pancreatic Cancer The United States experience. Int. J. Pancreatol (1991) 9:153–157.
   PubMedGoogle Scholar